SO
NVCT icon

STRS Ohio’s Nuvectis Pharma NVCT Stock Holding History

STRS Ohio’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,800
Closed -$47K – 2055
2024
Q1 		$47K Sell
5,800
-400
-6% -$3.4K ﹤0.01% 1770
2023
Q4 		$51K Buy
6,200
+2,300
+59% +$20.5K ﹤0.01% 1772
2023
Q3 		$50K Buy
3,900
+2,500
+179% +$36.2K ﹤0.01% 1793
2023
Q2 		$22K Buy
+1,400
New +$22.3K ﹤0.01% 1880

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

STRS Ohio's NVCT Position: Q2 2024 in Review

STRS Ohio sold out of Nuvectis Pharma (NVCT) in Q2 2024, closing a stake of 5,800 shares — an estimated $47K sold.

STRS Ohio first reported a position in NVCT in Q2 2023 and held it in 4 quarters. The position peaked at $51K in Q4 2023. 41 funds tracked by Wall St. Rank hold NVCT as of Q2 2024.

  • STRS Ohio reported no remaining Nuvectis Pharma position as of Q2 2024 after selling out during the quarter.
  • STRS Ohio sold 5,800 Nuvectis Pharma shares in Q2 2024, an estimated $47K.
  • STRS Ohio first reported a position in Nuvectis Pharma in Q2 2023 and held it in 4 quarters.
  • STRS Ohio's Nuvectis Pharma position peaked at $51K in Q4 2023.
  • 41 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2024.

Based on STRS Ohio's 13F filing for Q2 2024, filed 5 Aug 2024.